Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01666210 · ClinicalTrials.gov registry record · Phase 2
Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery
A Phase 2 study of Ocular Inflammation and Pain, sponsored by Ocular Therapeutix.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT01666210 is a Phase 2 study of Ocular Inflammation and Pain that has completed, run by Ocular Therapeutix. The registered enrollment target is 60 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01666210, a Phase 2 study of Ocular Inflammation and Pain, has completed, sponsored by Ocular Therapeutix.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the safety and efficacy of OTX-DP as a sustained release drug (dexamethasone) depot when placed in the canaliculus of the eyelid for the treatment of ocular inflammation and pain in subjects who have undergone cataract extraction with intra-ocular lens implantation.
Conditions Studied
Interventions
- DRUG OTX-DP (Dexamethasone punctum plug)
- DRUG Placebo Vehicle Punctum Plug
Study Locations (1)
Illinois
- Chicago Cornea Consultants, Ltd. - Hoffman Estates
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2012-10 |
| Est. Completion | 2013-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01666210
The ClinicalTrials.gov registry entry for NCT01666210 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ocular Therapeutix, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ocular Inflammation and Pain appearing as the primary indexed condition, and to 2 interventions - of which OTX-DP (Dexamethasone punctum plug) is the first listed.
NCT01666210 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT01666210 about?
NCT01666210 is a clinical study titled "Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery". To evaluate the safety and efficacy of OTX-DP as a sustained release drug (dexamethasone) depot when placed in the canaliculus of the eyelid for the treatment of ocular inflammation and pain in subjects who have undergone cataract extraction with intra-ocular lens implantation.
What is the current status of trial NCT01666210?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2012-10. Estimated completion is 2013-08.
What conditions does trial NCT01666210 study?
This clinical trial studies the following conditions: Ocular Inflammation and Pain.
What interventions are being tested in trial NCT01666210?
The interventions under investigation include: OTX-DP (Dexamethasone punctum plug) (DRUG), Placebo Vehicle Punctum Plug (DRUG).
Who is sponsoring clinical trial NCT01666210?
This trial is sponsored by Ocular Therapeutix, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01666210 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.